Please visit answersincme.com/QTQ860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in multiple myeloma discusses treatment sequencing in relapsed/refractory multiple myeloma (RRMM) and the integration of novel CAR T-cell therapies into the treatment paradigm. Upon completion of this activity, participants should be better able to: Identify the unmet therapeutic needs with current treatments for patients with relapsed/refractory multiple myeloma; Review the significance of the latest clinical data for the use of CAR T cells in pretreated patients with RRMM; and Outline clinical factors that may inform treatment sequencing strategies to optimize outcomes for patients.
View all episodes
